

## GLOSSARY OF TECHNICAL TERMS

*This glossary contains explanations of certain technical terms used in this Document in connection with us and our business. As such, some of these terms and their meanings may not correspond to standard industry definitions or usage of these terms and may not be comparable to similar terms adopted by other companies.*

|                     |                                                                                                                                                                                                           |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “ADA”               | American Diabetes Association                                                                                                                                                                             |
| “AEs”               | adverse events                                                                                                                                                                                            |
| “AHI”               | apnea-hypopnea index, a metric used to assess the severity of sleep apnea by measuring the average number of apnea and hypopnea events per hour of sleep                                                  |
| “β-arrestin”        | a family of intracellular adaptor proteins that regulate G protein-coupled receptor (GPCR) signaling by promoting desensitization, internalization, and G protein-independent pathways                    |
| “BLA”               | Biologics License Application, the regulatory submission filed with NMPA, the FDA, or other administrative agencies seeking approval to introduce a biologic product into the market                      |
| “cAMP”              | cyclic adenosine monophosphate, a molecule that transmits signals inside cells                                                                                                                            |
| “CDMO”              | contract development and manufacturing organization, a company that serves other companies in the pharmaceutical industry on a contract basis, providing drug development and drug manufacturing services |
| “C <sub>max</sub> ” | maximum plasma concentration, a pharmacokinetic parameter that measures the highest concentration of a drug in the blood, cerebrospinal fluid, or target organ after a dose is given                      |
| “CMC”               | chemistry, manufacturing, and controls, a term for the chemical composition, formulation, and quality control processes used in the manufacturing of a drug                                               |
| “CMO”               | contract manufacturing organization, a company that provides outsourced manufacturing services for pharmaceutical and biotechnology products                                                              |
| “Cohort”            | a group of participants as part of a clinical trial who share a common characteristic or experience within a defined period and who are monitored over time                                               |
| “CRO”               | contract research organization, a company that provides research services to pharmaceutical and biotechnology companies on a contract basis                                                               |

## GLOSSARY OF TECHNICAL TERMS

|                        |                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “CSO”                  | contract sales organization, a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of services for the development and commercialization of new drugs, medical devices, and other healthcare products                                                                                                                           |
| “C <sub>trough</sub> ” | the concentration of a drug in the bloodstream measured just before the next dose is administered                                                                                                                                                                                                                                                                                         |
| “DIO”                  | diet-induced obese                                                                                                                                                                                                                                                                                                                                                                        |
| “DPP-4”                | dipeptidyl peptidase-4, also known as adenosine deaminase complexing protein 2 or CD26 (cluster of differentiation 26), an enzyme expressed on the surface of most cell types and associated with immune regulation, signal transduction, and apoptosis                                                                                                                                   |
| “DTP”                  | direct-to-patient, a strategy where a healthcare company delivers products, services, or clinical trial support directly to patients, bypassing traditional intermediaries like pharmacies or healthcare providers, to enhance accessibility and engagement                                                                                                                               |
| “EASD”                 | European Association for the Study of Diabetes                                                                                                                                                                                                                                                                                                                                            |
| “FDA”                  | Food and Drug Administration                                                                                                                                                                                                                                                                                                                                                              |
| “GCP”                  | Good Clinical Practice                                                                                                                                                                                                                                                                                                                                                                    |
| “GLP-1”                | glucagon-like peptide-1, a peptide hormone that decreases blood sugar levels in a glucose-dependent manner by enhancing the secretion of insulin                                                                                                                                                                                                                                          |
| “GMP”                  | Good Manufacturing Practice                                                                                                                                                                                                                                                                                                                                                               |
| “GPCR”                 | G protein-coupled receptors, cell surface receptors that mediate cellular signaling in response to hormones, neurotransmitters, and other stimuli. When activated by a ligand, they undergo a conformational change that activates intracellular G proteins, triggering downstream signaling cascades. Due to their role in diverse physiological processes, GPCRs are major drug targets |
| “HbA1c”                | glycated hemoglobin, formed when hemoglobin joins with glucose in the blood and becomes glycated                                                                                                                                                                                                                                                                                          |
| “IND”                  | investigational new drug, an application in the drug review process required by a regulatory authority to decide whether a new drug is permitted to initiate clinical trials; also known as clinical trial application, or CTA, in China                                                                                                                                                  |

## GLOSSARY OF TECHNICAL TERMS

|            |                                                                                                                                                                                                                                                                                                                 |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “KOL”      | key opinion leader, an influential expert, typically a physician or researcher, whose expertise and authority in a specific medical field help shape clinical practices, research directions, or market perceptions for a company’s products or services                                                        |
| “LDL”      | low-density lipoprotein, a type of lipoprotein that carries cholesterol and other fats through the bloodstream                                                                                                                                                                                                  |
| “MASH”     | metabolic dysfunction-associated steatohepatitis, the liver manifestation of a metabolic disorder, and the most severe form of metabolic dysfunction-associated steatotic liver disease (MASLD)                                                                                                                 |
| “NCA”      | a pharmacokinetic analysis using the non-compartmental analysis method, which calculates drug exposure and elimination parameters directly from observed concentration-time data                                                                                                                                |
| “NDA”      | New Drug Application, a formal proposal submitted to NMPA, the FDA, or other administrative agencies seeking approval to introduce a new pharmaceutical into the market, including data on the drug’s safety, efficacy, and manufacturing process                                                               |
| “NEP”      | an enzyme that degrades vasoactive peptides, such as natriuretic peptides and bradykinin, and is a therapeutic target in cardiovascular diseases                                                                                                                                                                |
| “NMPA”     | the National Medical Products Administration of the PRC                                                                                                                                                                                                                                                         |
| “NRDL”     | the National Reimbursement Drug List, a list that names all the drugs covered by the medical insurance program in full or partially in China                                                                                                                                                                    |
| “OSA”      | a sleep disorder characterized by repeated episodes of upper airway obstruction during sleep, leading to disrupted breathing and poor sleep quality                                                                                                                                                             |
| “Phase I”  | a study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and if possible, to gain an early indication of its efficacy                                       |
| “Phase Ia” | an early study that primarily evaluates the safety, tolerability and pharmacokinetics of a drug in healthy subjects (the designations Phase Ia, Phase Ib and Phase Ic are assigned by us to reflect the specific clinical objectives of each study and not subject to a mandatory sequential naming convention) |

## GLOSSARY OF TECHNICAL TERMS

|             |                                                                                                                                                                                                                                                                                                                                                 |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| “Phase Ib”  | A study that further evaluates safety, tolerability and preliminary efficacy of a drug, usually in patients with the target disease (the designations Phase Ia, Phase Ib and Phase Ic are assigned by us to reflect the specific clinical objectives of each study and not subject to a mandatory sequential naming convention)                 |
| “Phase II”  | a study in which a drug is administered to a limited patient population to preliminarily evaluate the efficacy of the product for specific targeted diseases, to identify possible adverse effects and safety risks, and to determine optimal dosage                                                                                            |
| “Phase III” | a study in which a drug is administered to an expanded patient population generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to provide adequate information for the labeling of the product |
| “PI”        | principal investigator; the person(s) in charge of a clinical trial who prepares and carries out the clinical trial protocol, and analyzes the data and reports the results                                                                                                                                                                     |
| “QD”        | once per day, a term indicating the frequency at which a treatment or medication is administered                                                                                                                                                                                                                                                |
| “QM”        | once per month, a term indicating the frequency at which a treatment or medication is administered                                                                                                                                                                                                                                              |
| “QW”        | once per week, a term indicating the frequency at which a treatment or medication is administered                                                                                                                                                                                                                                               |
| “SMO”       | site management organization, an organization that has adequate infrastructure and staff to meet the requirements of the clinical trial protocol and provides clinical trial related services to a CRO, a pharmaceutical company, a biotechnology company, or a clinical site                                                                   |
| “TEAE”      | the adverse medical event occurring during the treatment period                                                                                                                                                                                                                                                                                 |
| “TG”        | triglyceride, a type of fat found in the blood, used as an indicator of metabolic and cardiovascular health                                                                                                                                                                                                                                     |
| “T2DM”      | type 2 diabetes mellitus, a form of diabetes characterized by high blood sugar, insulin resistance and relative lack of insulin; the pancreas in T2DM patient makes less insulin, and the body becomes resistant to insulin                                                                                                                     |